A conversation with Associate Professor Tom John and Professor Ben Solomon where they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.
Join us for a conversation with internationally recognized Medical Oncologists and researchers, Professor Ben Solomon & Associate Professor Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.
Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples.